Uppsala, March 27, 2020. Gradientech has been awarded with SEK 6.3M from the highly competitive BIO-X Accelerate program, to support the commercialization journey of its diagnostic system QuickMIC®. QuickMIC is an ultra-rapid system designed to provide fast and targeted treatment for sepsis patients.
Uppsala, February 26, 2020. Gradientech today announces the scientific publication of a navel multiplex fluidic chip for rapid antibiotic susceptibility testing (ASn. The chip can generate AST results within 2-4 ho urs, which is at least 20 hours faster than current AST methods used in hospital laboratories.
Gradientech AB (publ) year-end report for 2019 is now available in Swedish on the company’s website www.gradientech.se.
Gradientech AB:s (publ) bokslutskommuniké för 2019 finns nu tillgänglig på bolagets hemsida www.gradientech.se.
Uppsala, August 29, 2019. Gradientech AB today announces the trademark approval from the United States Patent and Trademark Office (USPTO) for QuickMIC®, its diagnostic system for ultrarapid antibiotic susceptibility testing. The registered trademark (Reg. No. 5817189) covers two classes for goods and services: Chemical and biological reagents for medical and veterinary use (IC 005) and diagnostic apparatus and instruments for analyzing cellular responses for medical and veterinary use (IC 010).
Uppsala, August 21, 2019. Gradientech AB, today announces that the company has received a Notice of Allowance from the United States Patent and Trademark Office for the patent application no. 14/903,032, “Use of a Fluidic Device”.
Gradientech has been invited to hold a short lecture at the Infection Week & Microbiological Spring Meeting (14-17 May) in Jönköping. The presentation will focus on QuickMIC™, the IVD system that Gradientech is currently developing for ultra-rapid antibiotic susceptibility testing (AST).
Uppsala, Sweden, April 12, 2019. Gradientech is displaying its QuickMIC™ system for the first time at ECCMID, the world’s premier clinical microbiology & infectious diseases conference, taking place in Amsterdam on April 13-16. During the ECCMID conference, the public will have the opportunity to preview the QuickMIC system and meet the experts behind its development.
Uppsala, Sweden, April 4, 2019. Swedish biotechnology company Gradientech today announced it has closed a fully subscribed rights issue totalling USD 4.6 million (SEK 42.5 million).Existing owners, as well as new parties appointed by Erik Penser Bank AB, who acted as financial advisor, have subscribed. Bird & Bird Lawyers acted as legal advisors.
Uppsala, March 20, 2079. Gradientech AB, a Swedish biotech and diagnostic company developing the next generation ultra-rapid antibiotic susceptibility testing (AST) system for appropriate treatment of sepsis, today announces that the Company has received a Notice of Allowance from the Chinese Patent Office (CHN) for the patent application no. 201480038696, “New Use of a Fluidic Device”.